Zinzino acquired the rights to the distributor database and associated customer register, inventory, and IP rights of the US-based direct sales company Bodē Pro through an asset acquisition. This is another strategic step in Zinzino’s growth plans, which focus on improving personal health and well-being on a global level with innovative biotechnology and a product portfolio marketed through direct sales.
Bodē Pro is a global direct sales company in the health segment, operating primarily in North America and Japan. Its brand portfolio offers a range of products in the health and wellness sector. The business has a total annual turnover of approximately $7 million. The collaboration with Zinzino is expected to add growth through the synergies that arise in the joint networks, combined with Zinzino’s test-based product concept and Bodē Pro’s innovative product range.
The partnership is also expected to accelerate Zinzino’s expansion in Japan. Approximately 55 percent of Bodē Pro’s total revenue currently comes from the Japanese market.
According to the asset purchase agreement, Zinzino will pay a fixed purchase price of $2 million upon completion, of which 50 percent will be settled through newly issued Zinzino shares. In addition, there will be a deferred purchase price of $0.4 million and additional purchase prices based on future sales development, which at maximum outcome may amount to $3.6 million. The additional purchase price shall be settled in full with newly issued Zinzino shares. The cash portion of the purchase price shall be paid from the company’s own cash reserves.
“Individualized advice and tailored solutions are the future, and not just in health and wellness,” says Dag Bergheim Pettersen, CEO of Zinzino. Together with BK Boreyko, CEO and founder of Bodē Pro, “Together, we have many years of combined industry experience and everything it takes to drive the modern, personalized shopping experience through direct sales.”
This acquisition follows other strategic acquisitions for Zinzino, including VMA Life in 2020, Enhanzz in 2022, Xelliss and ACN in 2024 and asset acquisitions of Zurvita, Valentus and Ecosystem in 2025.
